证券代码：688298 证券简称：东方生物 公告编号：2025-024 浙江东方基因生物制品股份有限公司 关于上海证券交易所对公司 2024 年年度报告 信息披露监管问询函的回复 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"、"公司"、 "本公司"）于近日收到上海证券交易所《关于浙江东方基因生物制品股份有限 公司 2024 年年度报告的信息披露监管问询函》（上证科创公函【2025】0152 号）， 现将问询函的相关问题做如下补充说明： 一、关于营业收入。公司主营业务为体外诊断试剂。2024 年，公司营业收 入为 8.28 亿元，同比增长 0.95%，归母净利润为-5.29 亿元，同比增亏 33.06%。 其中，境外收入 6.05 亿元，同比增长 23.14%；境内收入 2.07 亿元，同比下 滑 35.7%。公司 2024 年产品销量同比减少 16.1%。公司综合毛利率同比减少 请公司：（1）列示 2024 年境内主要销售产品类型、用途、收入金额、收 入占比及同比变 ...

Core Viewpoint - Shanghai Ruian Gene Technology Co., Ltd. is facing challenges in the biopharmaceutical industry, with a focus on maintaining stability and enhancing governance while navigating a decline in revenue and profit [5][6][10]. Meeting Procedures - The company has established guidelines for the annual shareholder meeting to ensure order and efficiency, requiring attendees to verify their identity and register in advance [1][2]. - Shareholders have the right to speak, inquire, and vote, with specific procedures for raising questions and participating in discussions [3][4]. Financial Performance - In 2024, the company reported a revenue of 242.31 million yuan, a decrease of 6.16% year-on-year, and a net profit attributable to shareholders of -15.76 million yuan, down 298.78% [6][21]. - The core business related to tumors generated revenue of 234.95 million yuan, reflecting a decline of 2.26% [6][21]. Business Developments - The company has made progress in its core business areas, including the addition of 75 new hospital admissions for its products, with specific gains in leukemia and lymphoma product admissions [7][8]. - The company has focused on digital and intelligent upgrades in laboratories, establishing a joint laboratory with Peking University to enhance AI applications in medical technology [8]. Governance and Compliance - The board of directors has adhered to legal and regulatory requirements, ensuring compliance in decision-making and operations, with all submitted proposals approved by shareholders [10][11]. - The supervisory board has conducted oversight on financial operations and internal controls, confirming that the company operates within legal frameworks and maintains financial integrity [18][19]. Future Plans - The company aims to enhance its research and development capabilities, focusing on molecular diagnostics for blood cancers and infectious diseases, with a commitment to affordable precision medicine [13][14]. - Plans for 2025 include advancing clinical projects and improving marketing mechanisms to increase product admissions in hospitals [14][15].

General Provisions - Guangzhou Wondfo Biotech Co., Ltd. aims to protect the legal rights of the company, shareholders, and creditors while regulating its organization and behavior according to relevant laws and regulations [1] - The company was established as a joint-stock company and registered with the Guangzhou Administration for Industry and Commerce [1] - The company was approved by the China Securities Regulatory Commission for its initial public offering of 22 million shares on June 30, 2015 [1] - The registered capital of the company is RMB 468,084,354 [1] Business Objectives and Scope - The company's business objective is to become a competitive manufacturer in the rapid in vitro diagnostic industry (POCT) and to provide services for public health [1] - The registered business scope includes the production and sale of medical devices, software development, artificial intelligence applications, and various consulting services [1] Shares - The company's shares are issued in the form of stocks with a par value of RMB 1 per share [2] - The total number of shares currently issued by the company is 468,084,354 [4] - The company cannot provide financial assistance for the purchase of its shares [4] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, participate in shareholder meetings, supervise the company's operations, and transfer their shares [6] - Shareholders must comply with laws and the company's articles of association, and they are responsible for paying their subscribed capital [8] - Shareholders holding more than 5% of voting shares must report any pledges of their shares to the company [9] Shareholder Meetings - The company holds annual and extraordinary shareholder meetings to decide on key matters such as business direction, capital changes, and profit distribution [10] - The notice for shareholder meetings must be sent out at least 20 days in advance for annual meetings and 15 days for extraordinary meetings [15] - The resolutions passed in shareholder meetings require a majority or two-thirds majority vote depending on the type of resolution [75][76]

证券代码：688068 证券简称：热景生物 公告编号：2025-044 北京热景生物技术股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述非职工代表董事将与公司职工代表大会选举出的 1 名职工代表董事共 同组成公司第四届董事会，公司第四届董事会董事自公司 2025 年第三次临时股 东大会审议通过之日起就任，任期三年。 公司第三届董事会成员在任职期间勤勉尽责，为促进公司规范运作和持续发 展发挥了积极作用，公司对各位董事在任职期间为公司发展所做的贡献表示衷心 感谢！ 特此公告。 北京热景生物技术股份有限公司董事会 附件： 北京热景生物技术股份有限公司（以下简称"公司"）第三届董事会即将届 满。根据《中华人民共和国公司法》 （以下简称《公司法》）、 《北京热景生物技术 股份有限公司章程》等有关规定，公司于 2025 年 6 月 16 日召开第三届董事会第 二十九次会议，审议通过了《关于选举第四届董事会非独立董事的议案》和《关 于选举第四届董事会独立董事的议案》。 经公司董事会提名，并经公 ...

Core Viewpoint - Awei Technology has experienced a decline in profitability despite its growth in the in vitro diagnostic field since its listing on June 16, 2021, with a market value decrease from 26.04 billion yuan to 14.23 billion yuan over four years [1][3][5] Business Overview - Awei Technology's main business includes the research, production, sales, and service of medical clinical testing analysis instruments and supporting in vitro diagnostic reagents and medical consumables [3] - The core product revenue structure shows that reagents account for the highest proportion at 53.44%, followed by instruments at 25.17% [3] Financial Performance - In 2021, Awei Technology achieved a net profit attributable to shareholders of 0.31 billion yuan, which decreased to 0.23 billion yuan by the end of the latest complete fiscal year in 2024, reflecting a cumulative profit growth decline of 26.97% [3] - The company has not reported any annual losses in the past four years, with profit growth occurring in three out of four years, representing a 75.0% success rate [3] - Revenue remained relatively stable, with 2.11 billion yuan in 2021 and 2.03 billion yuan in 2024, indicating a lack of growth momentum [3] Market Capitalization - Awei Technology reached a market capitalization peak of 30.94 billion yuan and a stock price of 45.5 yuan on June 16, 2021, but as of June 13, the market cap has decreased to 14.23 billion yuan, resulting in a market value loss of 16.71 billion yuan, or 54.02% [5]

文/梧桐数据中心 自2019年6月13日开板至今，科创板已历经六载。截至2025年6月13日，科创板上市公司数量达到588家，总 市值超过6.8万亿元，新一代信息技术、生物医药、高端装备制造等战略性新兴产业公司占比超八成。本文 盘点科创板开板六周年以来的十五项"第一"。 一、第一家科创板转板公司 观典防务技术股份有限公司（观典防务，688287）成立于2004年8月，是国内领先的无人机服务提供商，核 心业务包括无人机禁毒航测、飞行服务与数据处理，以及智能防务装备研发。2020年入选新三板精选层首 批企业，2021年北交所设立后平移成为北交所上市公司。 2021年10月20日，观典防务向上交所提交科创板转板申请；2022年1月27日，科创板上市委员会审议通过其 转板申请，观典防务成为首家北交所转科创板企业；2022年3月31日，获上交所正式同意转板决定；2022年 5月25日，登陆科创板上市交易，证券代码688287。 转板上市当年，观典防务营业收入、扣非净利润最高，分别为2.9104亿元、0.7869亿元。根据公司2024年年 报披露，公司2024年实现营业收入8998.384万元，归母净利润-1.3588亿 ...

据了解，上证科创板医疗指数从科创板中选取不超过30家医疗领域的上市公司证券作为指数样本，以反 映科创板中医疗上市公司证券的整体表现。该指数以2022年12月30日为基日，以1000.0点为基点。 从指数持仓来看，上证科创板医疗指数十大权重分别为：惠泰医疗（11.45%）、联影医疗 （10.09%）、爱博医疗（6.94%）、奕瑞科技（6.44%）、南微医学（5.44%）、圣湘生物（5.0%）、心 脉医疗（4.74%）、海尔生物（4.22%）、亚辉龙（3.61%）、澳华内镜（3.52%）。 从上证科创板医疗指数持仓的市场板块来看，上海证券交易所占比100.00%。 金融界6月13日消息，上证指数低开低走，上证科创板医疗指数 (科创医疗，950255)报737.03点。 数据统计显示，上证科创板医疗指数近一个月上涨1.84%，近三个月下跌2.05%，年至今上涨1.64%。 从上证科创板医疗指数持仓样本的行业来看，医疗耗材占比45.39%、医疗设备占比33.24%、体外诊断 占比21.37%。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因子随 ...

锡业股份：拟1亿–2亿元回购公司股份 6月13日，蜂助手（301382）发布公告称，公司拟以自筹资金2.06亿元收购广州小当智慧科技有限公司 持有的广东丰当科技有限公司30%的股权。收购完成后，蜂助手将持有丰当科技100%的股权。此次收 购旨在整合产业链资源，推动公司募投项目落地。 6月13日，锡业股份（000960）发布公告称，公司拟使用自有资金或自筹资金回购公司股份，用于注销 并减少注册资本，回购价格不超过21.19元/股（含），回购资金总额不低于1亿元（含）且不超过2亿元 （含）。 资料显示，锡业股份成立于1998年11月，主营业务是锡、铜、锌、铟等金属矿的勘探、开采、选矿和冶 炼。 所属行业：有色金属–小金属–其他小金属 蜂助手：拟收购控股子公司丰当科技剩余30%股权 资料显示，蜂助手成立于2012年1月，主营业务是互联网数字化虚拟商品综合服务。 所属行业：通信–通信服务–通信应用增值服务 *ST工智：收到深交所股票终止上市决定 6月13日，*ST工智（000584）发布公告称，公司收到深圳证券交易所关于股票终止上市的决定。公司 股票6月20日复牌并进入退市整理期，退市整理期的交易期限为15个交易日， ...

2、董事长好!请问董事长，股票一直在净资产下面，公司 近期是否有计划提升市值计划。 答：尊敬的投资者，您好！公司于 2025 年 4 月 25 日披露 了《2025 年度估值提升计划》，公司拟通过提升经营效率、 积极寻求投资并购、持续现金分红、适时开展中长期激励计划、 优化信息披露与投资者关系管理等举措，提升公司投资价值和 股东回报能力，推动公司投资价值合理反映公司质量，增强投 资者信心、维护全体股东利益，促进公司高质量发展。感谢您 的关注！ 3、陈董您好，2023 年检测业务萎缩，公司急需新的增长 点， 投资者普遍关心公司的创新业务扩展，比如通过并购快 速获取技术和市场，增加市占率， 请问公司是否切入传染病 产业链上的疫苗或创新药领域，以应对后疫情时代的业绩挑 战。 答：尊敬的投资者您好！目前公司暂未切入传染病产业链 的疫苗或创新药领域。公司正聚焦现有核心技术优势，从两方 证券代码：002932 证券简称：明德生物 武汉明德生物科技股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 业绩说明会 ...

Core Viewpoint - Haobor (688656.SH) is engaged in the research, production, and sales of in vitro diagnostic reagents, focusing on allergy and autoimmune disease testing [1] Company Overview - The company has reported normal daily operations with no significant changes [1] - There have been no major adjustments in the market environment or industry policies [1] - Production costs and sales conditions have not experienced significant fluctuations [1] - Internal production and operational order remains normal [1]